<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-001496
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20020604
<ITEMS>5
<ITEMS>7
<FILING-DATE>20020604
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02670208
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v82181e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc. Form 8-K on 6/04/02</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P align="left"><FONT size="2">Date of Report (Date of earliest reported) June&nbsp;4, 2002</FONT>

<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>

<HR width="26%" align="center" size="1" noshade>

<DIV align="center"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></DIV>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="34%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">Delaware</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">0-26323</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2"><HR size="1" noshade></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(State or other jurisdiction<BR>of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">(Commission<BR>File Number)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">(IRS Employer<BR>Identification No.)</FONT></TD>
</TR>
</TABLE>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="51%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="21%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="22%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top" nowrap><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>Woodland Hills, California</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="bottom"><FONT size="2">91367</FONT></TD>
        <TD valign="bottom"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><FONT size="2"><HR size="1" noshade></FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(Address of principal executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap valign="top"><FONT size="2">(Zip Code)</FONT></TD>
        <TD align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>

<P align="left"><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716</FONT>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v82181exv99w1.htm">EX-99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on June&nbsp;3, 2002, which announced
that it has entered into a cooperative Research and Development Agreement with
the Department of Energy&#146;s Pacific National Laboratory for a project entitled
&#147;Anti-Cytokine Antibodies for Treating Immune Mediated Diseases&#148; for the
development of high affinity humanized antibodies to gamma interferon. A copy
of such press release is incorporated herein by reference and is attached as an
exhibit to this Form&nbsp;8-K.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P><FONT size="2">(c)&nbsp; Exhibits.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="12%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="83%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Press Release, dated June&nbsp;3, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="50%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="top">
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD colspan="2"><FONT size="2">ADVANCED BIOTHERAPY, INC.<BR>(Registrant)</FONT></TD>
</TR>

<TR><TD>&nbsp;<BR>&nbsp;</TD></TR>
<TR valign="top">
        <TD><FONT size="2">Date: June&nbsp;4, 2002</FONT></TD>
        <TD><FONT size="2">By:&nbsp;</FONT></TD>
        <TD align="left"><FONT size="2">/s/Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD colspan="2"><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade color="#000000"></TD>
</TR>
<TR valign="top">
        <TD colspan="2">&nbsp;</TD>
        <TD><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated June&nbsp;3, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v82181exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc. Exhibit to Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="right"><FONT size="2">EXHIBIT 99.1</FONT>

<P align="center"><FONT size="2"><B>U.S. Department of Energy Approves Cooperative Research and Development<BR>
Agreement to Develop Humanized Antibodies To Gamma Interferon</B></FONT>

<P><FONT size="2">Woodland Hills, CA. June&nbsp;3, 2002. Advanced Biotherapy Inc. (OTCBB:ADVB)
announced today that it has entered into a Cooperative Research And Development
Agreement (CRADA)&nbsp;with the Department of Energy&#146;s (DOE)&nbsp;Pacific Northwest
National Laboratory (PNNL)&nbsp;for a project entitled &#147;Anti-Cytokine Antibodies for
Treating Immune Mediated Diseases&#148; for the development of high affinity
humanized antibodies to gamma interferon. The research is funded through the
&#147;Initiatives for Proliferation Prevention Program (IPP),&#148; a DOE program.
</FONT>
<P><FONT size="2">Under the terms of the CRADA, Battelle, which operates PNNL for the DOE, will
grant Advanced Biotherapy a non-exclusive, non-transferable, royalty-free,
field-of-use license to any inventions Battelle derives under this CRADA.
Advanced Biotherapy also has a first option to negotiate for greater rights,
such as exclusive, transferable, domestic and foreign marketing and development
rights. If Advanced Biotherapy obtains the right to sublicense, the sublicenses
must be royalty-bearing, and, subject to negotiation, Advanced Biotherapy will
pay a reasonable royalty to Battelle, which will share prospective royalties
with the Russian research facilities, upon commercialization of the antibodies.
</FONT>
<P><FONT size="2">The initial humanized antibody development is being funded and conducted at the
Institute of Immunological Engineering, a Biopreparat institution, located in
Moscow, Russia and with scientists at PNNL, located in Richland, Washington.
The availability of future additional funding by the DOE is based on the
progress of the research. The IPP program&#146;s purpose is to foster collaboration
between American and Russian scientists in the pursuit of commercially viable
projects to further deter proliferation of weapons of mass destruction.
</FONT>
<P><FONT size="2">The Russian scientists have created unique humanized antibodies to gamma
interferon, a major step toward treatment of certain autoimmune diseases. Until
recently, many treatments employing antibodies were derived from mice, which
were effective but could only be used one or two times before the human body
rejected them. Antibodies are proteins that bind to and disable foreign
proteins, called antigens. With humanized antibodies, the body could
potentially accept them over longer periods of time, thus providing for
long-term treatment.
</FONT>
<P><FONT size="2">Advanced Biotherapy collaborated with New Horizons Diagnostics, Inc. of
Columbia, Maryland, in the design and implementation of this project. The
hybridoma to produce the humanized antibodies to gamma interferon has already
been completed for Advanced Biotherapy&#146;s first pro-inflammatory targets under
its &#147;Method of Use Patent&#148; issued by the United States Patent and Trademark
Office on December&nbsp;25, 2001. It is expected that these antibodies will likely
be used first in human clinical trials for the treatment of Multiple Sclerosis
(MS)&nbsp;and Rheumatoid Arthritis (RA)&nbsp;followed by studies for other autoimmune
diseases for which patents are pending.
</FONT>
<P><FONT size="2">Commenting on the project award, Edmond Buccellato, Advanced Biotherapy&#146;s CEO,
stated, &#147;We are pleased to have been chosen for this program by PNNL and to be
working with such talented and esteemed immunologists in the Russian scientific
community. We are excited about the prospects of advancing the
commercialization of our therapeutic strategy to treat autoimmune diseases
through our recently issued patent for the exclusive use of antibodies to gamma
interferon for the treatment of MS and RA, juvenile RA, psoriatic RA (a form of
psoriasis) and ankylosing spondylitis (an autoimmune disease that causes the
spine to become inflamed and stiffened). The treatments of other autoimmune
diseases, for which patents are pending, are also being considered for clinical
trial study. This collaboration allows us begin moving toward the conduct of
clinical trials in the United States using humanized antibodies for these
debilitating and often life-threatening diseases.&#148;
</FONT>
<P><FONT size="2">PNNL is a DOE research facility that delivers breakthrough science and
technology in the areas of environment, energy, health, fundamental sciences
and national security. IPP is an Energy Department program established in 1994
to create non-defense jobs for former Soviet Union weapon scientists by linking
them with U.S. companies interested in commercializing their novel
technologies.
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the anticipated
results or other expectations expressed in our forward-looking statements. The
risks and uncertainties which may affect the development, operations and
results of our business include, but are not limited to the following: risks
associated with government sponsored and funded programs, the uncertainties of
research and product development programs, the uncertainties of the regulatory
approval process, the risks of clinical trials, the risks of competitive
products, the risks of our current capital resources, the uncertainties as to
the availability of future capital and our future capital requirements, and
the risks associated with the extent and breadth of the Company&#146;s patent
portfolio. The foregoing discussion of the effect of the patent issued
involves risks and uncertainties, including but not limited to the risks that
third parties may be successful in challenging the patent; or that granted
claims may be held invalid or interpreted differently by a court of law; or
that new technologies will be developed that are superior in treating the
diseases targeted by Advanced Biotherapy, Inc. Readers are cautioned not to
place reliance on these forward-looking statements, which speak only as of the
date the statements were made. See the Company&#146;s public filings with the
Securities and Exchange Commission for further information about risks and
uncertainties that may affect the Company and the results or expectations
expressed in our forward-looking statements, including the section captioned
&#147;Factors That May Affect The Company&#148; contained in the Company&#146;s Annual Report
on Form&nbsp;10-KSB for the fiscal year ended December&nbsp;31, 2001.
</FONT>
<P><FONT size="2"><I>Contact:</I>
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="5%">&nbsp;</TD>
        <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD colspan="3" align="left" valign="top"><FONT size="2">Advanced Biotherapy, Inc.</FONT></TD>
</TR>

<TR valign="bottom">
        <TD colspan="3" align="left" valign="top"><FONT size="2">Edmond Buccellato, 818/883-6716, Ext. 2</FONT></TD>
</TR>

<TR valign="bottom">
        <TD colspan="3" align="left" valign="top"><FONT size="2">Keith Gregg, 818-883-6716, Ext. 3</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">E-mail:&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">ed@advancedbiotherapy.com</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">keith@advancedbiotherapy.com</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Website:&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">www.advancedbiotherapy.com</FONT></TD>
</TR>
</TABLE>

<P><FONT size="2">Pacific Northwest National Laboratory<BR>
Staci Maloof, 509/372-6313<BR>
E-mail: staci.maloof@pnl.gov<BR>
Website: www.pnl.gov/news
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
